149results about How to "Good crystal stability" patented technology

The invention relates to a novel crystalline form of pregabalin drug for treating epilepsy and neuropathic pain and its preparation method. Compared to others pregabalin with agraphitic form and other forms, pregabalin with the novel crystalline form has good stability and is suitable for mass production. Pregabalin with the novel crystalline form uses Cu-Ka radiation and its X-ray powder diffraction has characteristic peak at 9.5(9.3), 12.3(7.2), 16.7(5.3), 18.4(4.8), 19.9(4.5) and 23.3(3.8) with the coordinate of 2-theta and interplanar spacing (d).

A lithium-containing complex oxide represented by the following formula 1: LixNi1-y-z-v-wCoyAlzM1

The invention discloses a metal ceramic reinforced body which is formed by zirconia alumina, Cr-Fe powder and an organic binding agent after being sintered. A plurality of through holes are uniformly arranged on a sintered and moulded block body; the through holes are arranged on the upper end face and the lower end face, and through grooves are arranged on four side faces. According to the metal ceramic reinforced body, grooves at edge portions of two adjacent reinforced bodies form an intact through hole after different reinforced bodies are spliced together, and metal liquid is poured into the through holes, so that metallic phase can infiltrate among ceramic particles and uniformly wrap ceramic phase. Not only toughness and abrasive resistance of product ceramic are enhanced, but also heat-vibration resistance is improved.

A thermal barrier coating material can prevent spall-off from occurring during operation at high temperatures and has a high heat insulating effect. A turbine parts and a gas turbine that are protected with the thermal barrier coating material are also provided. The thermal barrier coating material of the present invention comprises a ceramic layer 23, which is formed on a high temperature heat-resistant alloy base 21 to protect the base 21 from high temperatures, the ceramic layer 23 being applied via a bonding coat layer 22 provided as a metal bonding layer and is made of ZrO2 with Er2O3 added thereto as a stabilizing agent. The turbine parts and the gas turbine of the present invention are coated with the thermal barrier coating material on the surfaces thereof.

The invention relates to a lenvatinib mesilatee polymorph and a preparation method thereof. In particular, the present invention provides a novel crystalline form of a lenvatinib mesilatee dimethyl sulfoxide solvate and a preparation method of the novel crystalline form. The novel crystalline form of the present invention has an excellent crystal form and chemical stability, and better flowability.

An object of the present invention is to provide a crystal of a nitride of a Group-13 metal on the Periodic Table which has good crystallinity and has no crystal strain, and to provide a production method for the crystal. The crystal of a nitride of a Group-13 metal on the Periodic Table of the present invention, comprises oxygen atom and hydrogen atom in the crystal and has a ratio of a hydrogen concentration to an oxygen concentration therein of from 0.5 to 4.5.

A cathode active material that is able to improve storage characteristics without deteriorating charging and discharging capacity is provided. By mixing lithium nickel containing composite oxide particles comprising a layered rock-salt type crystal structure, a lithium compound, and an alkali metal compound; calcining the mixed powder at a temperature range of 800° C. to 1000° C.; washing and removing alkali metal other than lithium; mixing washed calcined particles with a lithium compound again; calcining the mixture in an oxidizing atmosphere at a temperature range of 600° C. to 800° C., lithium nickel containing composite oxide comprising a layered rock-salt type crystal structure and a peak intensity ratio of (003) plane with respect to (104) plane of 1.2 or more that are obtained by X-ray powder diffraction using Cu-Kα ray as an X-ray source is obtained.

The invention relates to lysine rheinic acid, a method for making same, and the application in treatment of tumor. The method is characterized in that the carboxyl of rheinic acid in the solution and the amino of lysine to form a salt structure to enhance the degree of solubility of rheinic acid in the solution; propanone or absolute alcohol is used to make lysine rheinic acid be separated out in a crystallization form, and the stable lysine rheinic acid crystallization is obtained by separating, purifying and drying; lysine rheinic acid has a appreciable inhibitory action for proliferation and growth of tumour cell, proved by vitro and vivo experiments. The lysine rheinic acid will become an ideal candidate drug for treating tumor.

A thermal barrier coating material can prevent spall-off from occurring during operation at high temperatures and has a high heat insulating effect. A turbine parts and a gas turbine that are protected with the thermal barrier coating material are also provided. The thermal barrier coating material of the present invention comprises a ceramic layer 23, which is formed on a high temperature heat-resistant alloy base 21 to protect the base 21 from high temperatures, the ceramic layer 23 being applied via a bonding coat layer 22 provided as a metal bonding layer and is made of ZrO2 with Er2O3 added thereto as a stabilizing agent. The turbine parts and the gas turbine of the present invention are coated with the thermal barrier coating material on the surfaces thereof.

The invention belongs to the technical field of lithium ion battery secondary batteries, and provides a preparation method of a lithium-rich manganese-based precursor. A fluorine and magnesium co-doped lithium-rich manganese-based precursor is prepared by a double-system co-precipitation method, the preparation method is simple in process and convenient to operate, and magnesium ions and fluorineions can be uniformly doped in a lithium-rich manganese-based material. The invention also provides the lithium-rich manganese-based precursor prepared by the preparation method, a lithium-rich manganese-based positive electrode material prepared from the lithium-rich manganese-based precursor and a lithium ion battery containing the positive electrode material. The lithium-rich manganese-based positive electrode material prepared by the preparation method disclosed by the invention can effectively improve crystal form stability of the material and inhibit voltage attenuation, and the preparedlithium ion battery has very good electrochemical performance.

The invention relates to I-type crystallization of N-n-propyl-3-(4-methylphenyl)-4-(4-mesylphenyl)-2,5-dihydropyrrole-2-ketone and a manufacturing method thereof. The method comprises the step of crystallizing any crystal form of or amorphous N-n-propyl-3-(4-methylphenyl)-4-(4-mesylphenyl)-2,5-dihydropyrrole-2-ketone solid with a polar organic solvent or aqueous solution thereof to obtain the I-type crystallization of N-n-propyl-3-(4-methylphenyl)-4-(4-mesylphenyl)-2,5-dihydropyrrole-2-ketone. The obtained I-type crystallization of N-n-propyl-3-(4-methylphenyl)-4-(4-mesylphenyl)-2,5-dihydropyrrole-2-ketone has favorable crystal form stability and chemical stability, and the utilized crystallization solvent has low toxicity and less residue, thereby the invention can be better used for clinical treatment.

To provide an optical recording medium and the like that is adapted to higher density and higher speed recording of 8 times or more than that of DVD (about 28 m / sec or more) and that exhibits superior repeating and reservation properties. An optical recording medium is provided that comprises a substrate, and a recording layer, wherein at least one of recording, reproducing, erasing, and rewriting of information is carried out by means of reversible phase changes at marks on the recording layer, the reversible phase changes at marks are induced between crystalline and amorphous states by laser irradiation, the length of the respective marks is 0.4 μm or less in the traveling direction of the laser irradiation, and the recording layer has a composition expressed by the formula: InαSbβ, wherein α and β are atomic percent of the respective elements; 0.73≦β / (α+β)≦0.90, α+β=100, alternatively a composition expressed by the formula: MγInαSbβ, wherein M represents an element other than In and Sb or an element combination containing two or more elements other than In and Sb; α and β are atomic percent of the respective elements, γ is atomic percent of the element or sum of atomic percent of the respective elements; 0.73≦β / (α+β)≦0.90, 0<γ<α, α+β+γ=100.

A thermal barrier coating material that exhibits superior high-temperature crystal stability to YSZ, as well as a high degree of toughness and an excellent thermal barrier effect. Also provided are a thermal barrier coating, which has a ceramic layer formed using the thermal barrier coating material and exhibits excellent durability to heat cycling, and a turbine member and a gas turbine which are each provided with the thermal barrier coating. The thermal barrier coating material comprises mainly ZrO2 which contains Yb2O3 and Sm2O3 as stabilizers, wherein the amount of the stabilizers is not less than 2 mol % and not more than 7 mol %, and the amount of the Sm2O3 is not less than 0.1 mol % and not more than 2.5 mol %.

The invention discloses a (S)-(+)-3-aminomethyl-5-methyl hexanoic acid crystal (Pregabalin), which is characterized by the following: treating epilepsy, nervous pain and wide anxiety; possessing excellent stability; fitting for large scale of production; using Cu-Ka irradiation for Pregabalin; displaying feature peak at 9.6(2), 12.4(7.1), 18.5(4.8), 20.0(4.4) and 23.4(3.8) diffracted by X-ray powder at 2 thita and d value as crystal gap distance.

The invention relates to a novel crystal form of a JAK inhibitor and a preparation method thereof. The novel crystal form provided by the invention can be used for treating autoimmune diseases, especially rheumatoid arthritis. The novel crystal form provided by the invention has good stability, obvious process purification effect, and the solubility and moisture in conformity with the requirement of medicine usage. The preparation method of the novel crystal form is simple and low in cost, and is of great value to the optimization and development of the medicine in the future.

The invention provides a crystal form of S-(-)-ornidazol disodium phosphate hexahydrate. A preparation method of the crystal form of S-(-)-ornidazol disodium phosphate hexahydrate is simple, and is suitable for industrial production. The crystal form of S-(-)-ornidazol disodium phosphate hexahydrate has high purity and good stability.

A cathode active material that is able to improve storage characteristics without deteriorating charging and discharging capacity is provided. By mixing lithium nickel containing composite oxide particles comprising a layered rock-salt type crystal structure, a lithium compound, and an alkali metal compound; calcining the mixed powder at a temperature range of 800° C. to 1000° C.; washing and removing alkali metal other than lithium; mixing washed calcined particles with a lithium compound again; calcining the mixture in an oxidizing atmosphere at a temperature range of 600° C. to 800° C., lithium nickel containing composite oxide comprising a layered rock-salt type crystal structure and a peak intensity ratio of (003) plane with respect to (104) plane of 1.2 or more that are obtained by X-ray powder diffraction using Cu-Kα ray as an X-ray source is obtained.

The invention relates to a novel crystalline form of mitiglinide drug for treating diabetes, composite comprising same and its preparation process. Mitiglinide is a medicine for treating Type-11 diabetes, and its chemical name is (-)-2(s)-benzyl-4-oxy-4-(cis-perhydro iso indole -2-yl) calcium butyrate dihydrate. The novel crystalline form has high stability.

The present invention relates to the dimethyl sulfoxide solvate of 3-[5-(2-fluorophenyl)-[1,2,4]oxdiazole-3-yl]benzoic acid, wherein the dimethyl sulfoxide solvate has characteristics of good stability, high purity, excellent particle and excellent shape, and is suitable for pharmaceutical preparation applications. The present invention further relates to a preparation method of the dimethyl sulfoxide solvate, a pharmaceutical composition of the dimethyl sulfoxide solvate, and uses of the dimethyl sulfoxide solvate in preparation of drugs for treatment of genetic diseases.

The invention provides a preparation method of a photocatalyst having the near-infrared responsiveness and taking porous silicon dioxide fibers as a carrier, and belongs to the technical field of nanoscale science. Firstly, a rare earth oxide is used as a raw material and core-shell type nano-catalyst particles with uniform particle size distribution and near-infrared responsiveness are obtained by adopting a hydrothermal method; secondly, the silicon dioxide fibers with porous structures are prepared through combination of a template method with an electrostatic spinning technology; and finally the uniform core-shell type nano-catalyst particles are loaded on the porous silicon dioxide fibers. The core-shell type nano-catalyst particles are uniformly distributed on the surfaces and the inner walls of the prepared porous silicon dioxide fibers, so that good dispersibility and high stability are shown. In addition, the preparation method is low in cost, and the light response range of the photocatalyst can be extended to a near-infrared region.

A titanylphthalocyanine crystal having an X-ray diffraction spectrum having plural diffraction peaks and a primary particle diameter not greater than 0.2 μm, wherein a maximum diffraction peak is observed at a Bragg (2 θ) angle of 27.2±0.2°; main peaks are observed at 9.4°, 9.6° and 24.0°; and a minimum diffraction peak is observed at 7.3°; and preferably no diffraction peak is observed at an angle greater than 7.3° and less than 9.4° when a specific X-ray of CuKα having a wavelength of 1.542 Å irradiates the titanylphthalocyanine crystal.

The invention provides a novel crystal form of (1S, 4R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl) pyridine-3-yl) ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl) amino) pyrimidine-2-yl) cyclohexane formamide (a compound represented by a formula (I)) and a preparation method thereof.

A zinc oxide-alumina-silica-based crystallized glass containing zinc oxide, alumina and silica as main components, and zirconia as a nucleating agent, the main components comprising at a ratio of 20-30% by mass of zinc oxide, 15-25% by mass of alumina and 50-60% by mass of silica, the main components amounting to 100% by mass in total, the nucleating agent being contained in an amount of 3-6 parts by mass based on 100 parts by mass of the main components, and at least one component selected from the group consisting of lithium oxide, sodium oxide, potassium oxide, diphosphorus pentoxide, niobium oxide and tantalum oxide being contained as a modification component in addition to the main components and the nucleating agent.

The invention belongs to the technical field of medicines, and particularly discloses two new crystal forms of deuterated AZD9291 and a preparation method of the crystal forms. The invention also discloses applications of the crystal forms of the deuterated AZD9291 in preparation of drugs for treating cancers. According to the invention, the results of the research on normal temperature and accelerated stability show that the deuterated AZD9291 crystal forms A and C provided by the invention are stable crystal forms and have good crystal form stability compared with other crystal forms by combining suspension experiments and DVS data.

The invention relates to a benzbromarone crystal form A applicable to the field of chemical pharmacy and a preparation method thereof. In an X-ray powder diffraction pattern represented by a 2theta angle, the error range of the 2theta angle is + / - 0.2. The benzbromarone crystal form A has the basic X-ray powder diffraction pattern. In the differential scanning calorimetry pattern, when the heating speed is 10 DEG C per minute, the benzbromarone crystal form A has a maximal endothermic peak, and the melting point value of the benzbromarone crystal form A is 152.23 DEG C. The method comprises the following steps: under the condition of 25 DEG C, taking 1.0g of benzbromarone crystal form A, and adding 10ml of trichloromethane, wherein the solid is completely dissolved, and the solution is clear; taking 1.25g of benzbromarone crystal form A, and adding 25ml of N,N-dimethylformamide, wherein the solid is slightly insoluble, and the solution is not clear; and crystallizing from a single solvent acetone to obtain the benzbromarone crystal form A. The crystal form has the advantages of high stability, simple preparation method, low cost, simple after-treatment, high product purity and fewer related substances.

The invention discloses dexlansoprazole-isonicotine eutectic and application of the eutectic. The eutectic is a crystalline complex combined by dexlansoprazole and isonicotine at a mole ratio of 1:1 in a non-covalent form; an X-ray powder diffraction spectrum of the eutectic comprises diffraction peaks expressed by the following 2 theta angles: 5.3-5.5 degrees, 10.7-10.9 degrees, 12.8-13.0 degrees, 14.9-15.1 degrees, 16.1-16.3 degrees, 18.4-18.6 degrees, 19.1-19.3 degrees, 19.9-20.1 degrees, 22.0-22.2 degrees, 22.6-22.8 degrees, 24.3-24.5 degrees, 25.8-26.0 degrees, 26.2-26.4 degrees, 27.0-27.2 degrees, 27.4-27.6 degrees, 31.4-31.6 degrees and 32.5-32.7 degrees. Compared with the prior art, the dexlansoprazole-isonicotine eutectic is excellent in crystal form stability and high in bioavailability, and has greater maximum apparent solubility in ultrapure water; a preparation method of the dexlansoprazole-isonicotine eutectic is simple, mild in condition and high in repeatability; a product can be conveniently, quickly and stably obtained; the crystal form purity of the product is high; obvious raw material impurities and residual solvents do not exist.

The invention relates to a high-temperature flue gas denitration catalyst and a preparation method thereof. The method comprises the following steps: preparing a mixed solution containing TiO2, a zircon salt and citric acid, adding a powdery silicoaluminophosphate molecular sieve into the mixed solution, dipping, and drying and roasting to obtain a TiO2-ZrO2-molecular sieve composite carrier; thendipping the composite carrier into a dipping solution containing an active component and an auxiliary component, drying and roasting to obtain denitration catalyst powder, and kneading, aging, extruding, drying and roasting the powder to obtain the honeycomb denitration catalyst. The method is simple in process, environmentally friendly and economical, and the prepared denitration catalyst can avoid transformation of anatase TiO2 crystal forms and has the advantages of being high in high-temperature denitration activity, good in thermal stability, high in N2 selectivity and the like.

The present invention provides a crystal form represented by a formula (A) of a compound, and a preparation method thereof, a composition, and applications of the crystal form and the composition in preparation of angiotensin II receptor antagonists, or in preparation of drugs for prevention and / or treatment of hypertension, chronic heart failure, and diabetic nephropathy. The formula (A) is defined in the specification.